



GARDELLA GRACE

Patrick J. Halloran



Patrick J. Halloran, Ph.D.

Patent Procurement

703-740-5611

phalloran@gardellagrace.com

Dr. Patrick Halloran is a registered patent attorney and has served as an advisor and counselor in the pharmaceutical, biotechnology, and life science fields for more than 25 years. His diverse experience involves counseling large, mid-size, and start-up pharmaceutical and biotechnology companies, as well as universities and investment groups. His expansive technical, legal, and industry expertise has guided client work on in-license and out-license targets, freedom-to-operate and validity opinions, infringement assertions, trademark registration, and patent prosecution.

In 2001, Dr. Halloran joined Aventis Pasteur, Inc. (now Sanofi Pasteur, Inc.), eventually becoming Senior Director of Intellectual Property. In that role, he was responsible for domestic and international intellectual property issues relating to various projects within the company. Throughout his career, Dr. Halloran has worked extensively with outside counsel from other regions and countries including Australia, Europe, Canada, China, India, Japan, and New Zealand and Singapore.

Dr. Halloran earned a Ph.D. in Microbiology and Immunology from The University of Health Sciences, The Chicago Medical School. His doctoral project related to the biochemical characterization and cloning of the cDNA encoding a porcine cytolytic trigger molecule which was identified as an Fc-g receptor. He also performed post-doctoral studies at The National Cancer Institute relating to novel approaches for gene therapy of melanoma.

Education

- Chicago-Kent College of Law, Illinois Institute of Technology (J.D.)
- Chicago Medical School at Rosalind Franklin University U-Med & Science (Ph.D.)
Microbiology and Immunology
- Augustana College (B.A.)
Biology

Admissions

- Admitted in IL only; practice is limited to matters and proceedings before federal courts and agencies
- Illinois
- U.S. Patent and Trademark Office

Representative Presentations and Publications:

- Vacchiano, E. and Halloran, P.J. Amarin's U.S. Patent protection for Vascepa. Seeking Alpha (Nov. 30, 2018)
- Siders W.M., Halloran, P.J., Fenton R.G. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Ther. 1998 Sep-Oct; 5(5):281-91.
- Halloran P.J., Fenton R.G. Irreversible G2-M arrest and cytoskeletal reorganization induced by cytotoxic nucleoside analogues. Cancer Res. 1998 Sept 1:58(17):3855-65.